Home » Topics » BioWorld Science

BioWorld Science
RSS

Prelude Therapeutics identifies new PRMT5 inhibitors

Sep. 12, 2018

Innate Tumor Immunity synthesizes new NLRP3 agonists for cancer

Sep. 12, 2018

RQx Pharmaceuticals and Genentech present antibacterial compounds

Sep. 12, 2018

SuPAR predicts chronic kidney disease progression in Black Americans

Sep. 12, 2018

Phase III study of Zerbaxa in HABP and VABP meets primary endpoints

Sep. 12, 2018

Trevena patents new delta-opioid receptor modulators

Sep. 12, 2018

Researchers present first-in-human data for AT-04A

Sep. 12, 2018

Regulation, edification, sedation: 2018 Laskers honor research on complexity beyond DNA

Sep. 12, 2018

European Commission approves Keytruda with pemetrexed and chemotherapy for first-line NSCLC

Sep. 12, 2018

Five Prime advances FIGHT study of bemarituzumab in gastric and gastroesophageal cancer

Sep. 12, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...